Log in Free sign up

Karuna Therapeutics (KRTX) News and press releases

News

From Benzinga Pro

Karuna Therapeutics: Q1 Earnings Insights

Karuna Therapeutics (NASDAQ:KRTX) reported its Q1 earnings results on Thursday, May 5, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Karuna Therapeutics Q1 EPS $(1.95) Down From $(1.10) YoY

Karuna Therapeutics (NASDAQ:KRTX) reported quarterly losses of $(1.95) per share. This is a 77.27 percent decrease over losses of $(1.10) per share from the same period last year.

What 4 Analyst Ratings Have To Say About Karuna Therapeutics

Analyst Ratings

Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings within the last quarter:

Mizuho Maintains Buy on Karuna Therapeutics, Raises Price Target to $190

News, Price Target, Analyst Ratings

Mizuho analyst Vamil Divan maintains Karuna Therapeutics (NASDAQ:KRTX) with a Buy and raises the price target from $178 to $190.

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Berenberg Initiates Coverage On Karuna Therapeutics with Buy Rating, Announces Price Target of $190

News, Price Target, Initiation, Analyst Ratings

Berenberg initiates coverage on Karuna Therapeutics (NASDAQ:KRTX) with a Buy rating and announces Price Target of $190.

Jefferies Maintains Buy on Karuna Therapeutics, Raises Price Target to $183

News, Price Target, Analyst Ratings

Jefferies analyst Chris Howerton maintains Karuna Therapeutics (NASDAQ:KRTX) with a Buy and raises the price target from $180 to $183.

Mizuho Maintains Buy on Karuna Therapeutics, Lowers Price Target to $178

News, Price Target, Analyst Ratings

Mizuho analyst Vamil Divan maintains Karuna Therapeutics (NASDAQ:KRTX) with a Buy and lowers the price target from $182 to $178.

Amid Russia's Invasion On Ukraine, Karuna Therapeutics Withdraws Guidance On Late-Stage Schizophrenia Trial

Biotech, Earnings, News, Health Care, Movers, Trading Ideas, General

Karuna Therapeutics Q4 EPS $(0.94) Down From $(0.89) YoY

Karuna Therapeutics (NASDAQ:KRTX) reported quarterly losses of $(0.94) per share. This is a 5.62 percent decrease over losses of $(0.89) per share from the same period last year.

Press releases

From Benzinga Pro

Karuna Therapeutics to Host Virtual Event Highlighting Clinical Program for Psychosis in Alzheimer's Disease

Webcast scheduled for Wednesday, May 25, 2022, at 8:00 a.m. ET Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living

Karuna Therapeutics Reports First Quarter 2022 Financial Results and Provides General Business Update

Completed enrollment in the Phase 3 EMERGENT-2 trial evaluating KarXT for the treatment of schizophrenia in the second quarter of 2022 Topline data from the Phase 3 EMERGENT-2 and EMERGENT-3 trials expected in the

Karuna Therapeutics to Present at the 2022 RBC Capital Markets Global Healthcare Conference

Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced

Karuna Therapeutics to Present at Upcoming Investor Conferences

Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced

Karuna Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides General Business Update

Topline data from the Phase 3 EMERGENT-2 and EMERGENT-3 trials expected in mid-2022 and in the second half of 2022, respectively Initiated the Phase 3 ARISE trial evaluating KarXT in adults with schizophrenia who